Poster Presentation (Exhibit Hall)
Date:	Monday, July 13, 2026
Time:	7:30am – 4:15pm BST
Session:	In-Person Posters Tuesday; Drug Development: Human
Topic:	Laromestrocel in Mild Alzheimer's Disease: Additional Phase 2a Clinical Data Analysis

Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer's disease and provided evidence-based support for further clinical development, were published in the peer-reviewed journal Nature Medicine in March 2025.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.